{"success":true,"data":{"pressRelease":{"id":"2942","rtpr_id":"nPn6FltJfa","ticker":"CORT","exchange":"NASDAQ","all_tickers":["CORT"],"title":"CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm","author":"PR Newswire","published_at":"2026-04-21T13:00:57.013Z","article_body":"CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm\n\nPR Newswire\n\nNEW YORK, April 21, 2026\n\nNEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the\nfollowing notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ:\nCORT).\n\n(https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.html)\n\nShareholders who purchased shares of CORT during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointment.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form-2/?id=185668&from=4\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4668631-1&h=2904141170&u=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fcorcept-therapeutics-incorporated-loss-submission-form-2%2F%3Fid%3D185668%26from%3D4&a=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fcorcept-therapeutics-incorporated-loss-submission-form-2%2F%3Fid%3D185668%26from%3D4)\n \n\nCLASS PERIOD: October 31, 2024 to December 30, 2025\n\nALLEGATIONS: According to the filed complaint, defendants made false\nstatements and/or concealed that: In light of the circumstances in which they\nwere made, not false and misleading. In truth, the FDA had told Corcept that\nit had concerns about the adequacy of the program assessing relacorilant's\neffectiveness in treating hypertension in patients with hypercortisolism,\nincluding the design of the GRACE study. The FDA had further told Corcept to\nexpect significant issues with the review if Corcept was to submit the NDA. As\na result, Defendants' positive statements concerning their interactions with\nthe FDA and their expectations that the relacorilant NDA would be approved,\nwere materially false or misleading.\n\nDEADLINE: April 21, 2026 Shareholders should not delay in registering for this\nclass action. Register your information here:\nhttps://securitiesclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form-2/?id=185668&from=4\n(https://securitiesclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form-2/?id=185668&from=4)\n\nNEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased\nshares of CORT during the timeframe listed above, you will be enrolled in a\nportfolio monitoring software to provide you with status updates throughout\nthe lifecycle of the case. The deadline to seek to be a lead plaintiff is\nApril 21, 2026. There is no cost or obligation to you to participate in this\ncase.\n\nWHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action\nlaw firm, and our mission is to protect the rights of all investors who have\nsuffered as a result of deceit, fraud, and illegal business practices. The\nGross Law Firm is committed to ensuring that companies adhere to responsible\nbusiness practices and engage in good corporate citizenship. The firm seeks\nrecovery on behalf of investors who incurred losses when false and/or\nmisleading statements or the omission of material information by a company\nlead to artificial inflation of the company's stock. Attorney advertising.\nPrior results do not guarantee similar outcomes.\n\nCONTACT:\nThe Gross Law Firm\n15 West 38th Street, 12th floor\nNew York, NY, 10018\nEmail: dg@securitiesclasslaw.com (mailto:dg@securitiesclasslaw.com)\nPhone: (646) 453-8903\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/cort-shareholder-alert-corcept-therapeutics-incorporated-securities-class-action-lawsuit-investors-with-losses-may-join--the-gross-law-firm-302748179.html\n(https://www.prnewswire.com/news-releases/cort-shareholder-alert-corcept-therapeutics-incorporated-securities-class-action-lawsuit-investors-with-losses-may-join--the-gross-law-firm-302748179.html)\n\nSOURCE The Gross Law Firm\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6FltJfa","title":"CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm","author":"PR Newswire","ticker":"CORT","created":"2026-04-21T13:00:57.013Z","tickers":["CORT"],"exchange":"NASDAQ","article_body":"CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm\n\nPR Newswire\n\nNEW YORK, April 21, 2026\n\nNEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the\nfollowing notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ:\nCORT).\n\n(https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.html)\n\nShareholders who purchased shares of CORT during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointment.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form-2/?id=185668&from=4\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4668631-1&h=2904141170&u=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fcorcept-therapeutics-incorporated-loss-submission-form-2%2F%3Fid%3D185668%26from%3D4&a=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fcorcept-therapeutics-incorporated-loss-submission-form-2%2F%3Fid%3D185668%26from%3D4)\n \n\nCLASS PERIOD: October 31, 2024 to December 30, 2025\n\nALLEGATIONS: According to the filed complaint, defendants made false\nstatements and/or concealed that: In light of the circumstances in which they\nwere made, not false and misleading. In truth, the FDA had told Corcept that\nit had concerns about the adequacy of the program assessing relacorilant's\neffectiveness in treating hypertension in patients with hypercortisolism,\nincluding the design of the GRACE study. The FDA had further told Corcept to\nexpect significant issues with the review if Corcept was to submit the NDA. As\na result, Defendants' positive statements concerning their interactions with\nthe FDA and their expectations that the relacorilant NDA would be approved,\nwere materially false or misleading.\n\nDEADLINE: April 21, 2026 Shareholders should not delay in registering for this\nclass action. Register your information here:\nhttps://securitiesclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form-2/?id=185668&from=4\n(https://securitiesclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form-2/?id=185668&from=4)\n\nNEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased\nshares of CORT during the timeframe listed above, you will be enrolled in a\nportfolio monitoring software to provide you with status updates throughout\nthe lifecycle of the case. The deadline to seek to be a lead plaintiff is\nApril 21, 2026. There is no cost or obligation to you to participate in this\ncase.\n\nWHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action\nlaw firm, and our mission is to protect the rights of all investors who have\nsuffered as a result of deceit, fraud, and illegal business practices. The\nGross Law Firm is committed to ensuring that companies adhere to responsible\nbusiness practices and engage in good corporate citizenship. The firm seeks\nrecovery on behalf of investors who incurred losses when false and/or\nmisleading statements or the omission of material information by a company\nlead to artificial inflation of the company's stock. Attorney advertising.\nPrior results do not guarantee similar outcomes.\n\nCONTACT:\nThe Gross Law Firm\n15 West 38th Street, 12th floor\nNew York, NY, 10018\nEmail: dg@securitiesclasslaw.com (mailto:dg@securitiesclasslaw.com)\nPhone: (646) 453-8903\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/cort-shareholder-alert-corcept-therapeutics-incorporated-securities-class-action-lawsuit-investors-with-losses-may-join--the-gross-law-firm-302748179.html\n(https://www.prnewswire.com/news-releases/cort-shareholder-alert-corcept-therapeutics-incorporated-securities-class-action-lawsuit-investors-with-losses-may-join--the-gross-law-firm-302748179.html)\n\nSOURCE The Gross Law Firm\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-21T13:00:57.066862415Z","server_sent_at_ms":1776776457066},"received_at":"2026-04-21T13:00:57.120Z","source_url":"https://www.prnewswire.com/news-releases/cort-shareholder-alert-corcept-therapeutics-incorporated-securities-class-action-lawsuit-investors-with-losses-may-join--the-gross-law-firm-302748179.html"},"analysis":{"id":"1908","press_release_id":"2942","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Allegations of concealing FDA concerns regarding lead asset relacorilant","Lawsuit claims FDA warned of significant NDA review issues"],"eventType":"legal_litigation","narrative":"The Gross Law Firm announced a class action lawsuit against Corcept Therapeutics on behalf of shareholders who purchased stock between October 31, 2024, and December 30, 2025.\n\nThe complaint alleges that the company made false statements by concealing FDA concerns regarding the adequacy of the GRACE study assessing relacorilant's effectiveness in treating hypertension.\n\nSpecifically, the suit claims the FDA warned of significant issues with the review if the NDA was submitted, contradicting the company's previous positive statements regarding approval expectations.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Class action alleges Corcept hid FDA concerns over relacorilant's study design and NDA viability."},"keyFigures":{},"quotedText":"the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant's effectiveness in treating hypertension in patients with hypercortisolism","namedEntities":{"people":[],"products":["relacorilant","GRACE study"],"companies":[{"name":"Corcept Therapeutics Incorporated","ticker":"CORT"},{"name":"The Gross Law Firm","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"The lawsuit alleges the company concealed FDA concerns regarding the GRACE study design and the NDA submission for lead asset relacorilant, directly challenging the validity of the company's primary growth driver."},"tickerRelevance":{"others":[],"primary":"CORT"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"The Gross Law Firm announced a class action lawsuit against Corcept Therapeutics on behalf of shareholders who purchased stock between October 31, 2024, and December 30, 2025.\n\nThe complaint alleges that the company made false statements by concealing FDA concerns regarding the adequacy of the GRACE study assessing relacorilant's effectiveness in treating hypertension.\n\nSpecifically, the suit claims the FDA warned of significant issues with the review if the NDA was submitted, contradicting the company's previous positive statements regarding approval expectations.","key_figures":{},"named_entities":{"people":[],"products":["relacorilant","GRACE study"],"companies":[{"name":"Corcept Therapeutics Incorporated","ticker":"CORT"},{"name":"The Gross Law Firm","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T18:43:37.723Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.453Z"}},"durationMs":176892,"modelName":"glm-4.7"}}